Hrt Financial LP Aligos Therapeutics, Inc. Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.89 - $1.36 $14,389 - $21,988	-16,168 Reduced 61.54%	10,105 $9,000
Q1 2023 May 12, 2023	SELL	$0.87 - $2.11 $34,787 - $84,370	-39,986 Reduced 60.35%	26,273 $22,000
Q4 2022 Feb 10, 2023	SELL	$0.89 - $28.0 $31,606 - $994,364	-35,513 Reduced 34.89%	66,259 $63,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.5 $36,902 - $957,385	-34,814 Reduced 25.49%	101,772 $111,000
Q2 2022 Aug 12, 2022	BUY	$1.04 - $2.14 $63,624 - $130,918	61,177 Added 81.13%	136,586 $165,000
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $128,152 - $751,666	61,612 Added 446.56%	75,409 $162,000
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.69 $158,389 - $244,068	13,797 New	13,797 $163,000

47.3M

1.4K

300

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $326M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.